Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC). By harnessing the unique regenerative powers of the liver, our mission is to build a healthier tomorrow for patients and address the liver community’s most pressing needs. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
Contact:
E-mail - Holly.kirkpatrick@interceptpharma.com
E-mail - Aryan.melville@interceptpharma.com
Link to Product Information Website »
Featured Content
